Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo.

Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo.
复制标题

DOI:
10.1021/acs.jmedchem.8b00405
复制
发表时间:
2018-06-28
影响因子:
7.3
通讯作者:
Wang TD
Wang TD
中科院分区:
医学1区
文献类型:
--
作者:
Chen J;Zhou J;Gao Z;Li X;Wang F;Duan X;Li G;Joshi BP;Kuick R;Appelman HD;Wang TD

文献摘要

参考文献

被引文献

相似文献

食管腺癌(EAC)是一种分子异质性疾病,发病率上升迅速,预后不良。我们开发了一种异二价肽,通过将针对EGFR或ErbB2的单体七肽以异二聚体的配置组合在一起,靶向检测早期Barrett肿瘤。对三甘醇连接体的结构进行了优化,以最大限度地结合细胞表面受体。Cy5.5标记的异源二聚体QRH*-KSP*-E3-Cy5.5与每个靶点都有特异性结合,荧光强度是单体的3倍,亲和力是单体的2倍。异种移植瘤体内摄取高峰出现在注射后2小时,全身清除时间为24小时。此外,在体外对人食道标本的配体结合进行了评估,发现对高度异型增生(HGD)或EAC的检测灵敏度为88%,特异度为87%。这种多肽异源二聚体在临床研究中显示出对早期Barrett瘤的靶向检测的前景。
Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early Barrett’s neoplasia by combining monomer heptapeptides specific for either EGFR or ErbB2 in a heterodimer configuration. The structure of a triethyleneglycol linker was optimized to maximize binding interactions to the surface receptors on cells. The Cy5.5-labeled heterodimer QRH*-KSP*-E3-Cy5.5 demonstrated specific binding to each target and showed 3-fold greater fluorescence intensity and 2-fold higher affinity compared with either monomer alone. Peak uptake in xenograft tumors was observed at 2 hours post-injection with systemic clearance by ~24 hours in vivo. Furthermore, ligand binding was evaluated on human esophageal specimens ex vivo, and 88% sensitivity and 87% specificity were found for detection of either high-grade dysplasia (HGD) or EAC. This peptide heterodimer shows promise for targeted detection of early Barrett’s neoplasia in clinical study.
DOI: 10.1016/0016-5085(93)90008-z
发表时间: 1993-07-01
期刊: GASTROENTEROLOGY
影响因子: 29.4
作者:
LEVINE, DS;HAGGITT, RC;REID, BJ
通讯作者: REID, BJ
DOI: 10.1038/86707
发表时间: 2001-04-01
影响因子: 46.9
作者:
Becker, A;Hessenius, C;Grötzinger, C
通讯作者: Grötzinger, C
DOI: 10.1021/mp500115x
发表时间: 2014-06-02
影响因子: 4.9
作者:
Luo H;Hong H;Yang SP;Cai W
通讯作者: Cai W
DOI: 10.1158/0008-5472.can-11-3893
发表时间: 2012-09-01
期刊: Cancer research
影响因子: 11.2
作者:
Dulak AM;Schumacher SE;van Lieshout J;Imamura Y;Fox C;Shim B;Ramos AH;Saksena G;Baca SC;Baselga J;Tabernero J;Barretina J;Enzinger PC;Corso G;Roviello F;Lin L;Bandla S;Luketich JD;Pennathur A;Meyerson M;Ogino S;Shivdasani RA;Beer DG;Godfrey TE;Beroukhim R;Bass AJ
通讯作者: Bass AJ
DOI: 10.1021/bc1004284
发表时间: 2011-07-20
影响因子: 4.7
作者:
Josan, Jatinder S.;Handl, Heather L.;Sankaranarayanan, Rajesh;Xu, Liping;Lynch, Ronald M.;Vagner, Josef;Mash, Eugene A.;Hruby, Victor J.;Gillies, Robert J.
通讯作者: Gillies, Robert J.